Trials / Terminated
TerminatedNCT04381494
Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.
Prospective, Interventional Pilot Study of Mobile Devices and Digital Applications to Detect Early Pneumonitis and Other Pulmonary Adverse Events in Unresectable Stage III Non-Small Cell Lung Cancer Patients on Durvalumab
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 130 Years
- Healthy volunteers
- Not accepted
Summary
A study of whether mobile devices can improve the detection of pulmonary AEs (including pneumonitis) in stage III NSCLC patients post-CRT, while on durvalumab.
Detailed description
Patients undergoing post-CRT treatment for lung cancer with consolidation durvalumab can experience pulmonary AEs that could become severe if not recognized and treated in time. Data collected will be used to evaluate the likelihood of early detection of pulmonary AEs in unresectable Stage III NSCLC patients on durvalumab. This project seeks to understand if multiparametric mobile technology collecting patient reported outcomes, vital signs, and respiratory function, integrate well into a patients daily life and aid physicians in early detection of pulmonary AEs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Multiparametric Mobile Technology | Using a spirometer, an armband, and a tablet to collect data. |
Timeline
- Start date
- 2020-04-27
- Primary completion
- 2022-01-27
- Completion
- 2022-01-27
- First posted
- 2020-05-08
- Last updated
- 2023-06-22
- Results posted
- 2023-06-22
Locations
18 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04381494. Inclusion in this directory is not an endorsement.